Journal of Infectious Diseases & Therapy
黑料网
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 1529
Indexed In
- Index Copernicus
- Google Scholar
- Open J Gate
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Immunogenic effect in CD1 mice upon phosphate addition to Chlamydia trachomatis serovar E rMOMP compositions adjuvanted with a TLR4 agonist and AlOOH carrier system
World Congress on Infectious Diseases
Lucian Visan1, Violette Sanchez1, Christelle Seraille1, Ausra Mancevsky2, Catherine Caillet1, Margaux Kania2 and Salvador F Ausar2
ScientificTracks Abstracts: J Infect Dis Ther
DOI:
Abstract
Genital infection with Chlamydia trachomatis is the most prevalent sexually transmitted disease. Effective vaccination
against this common disease will limit the transmission and morbidity associated with it. The objective of the study was
to assess the immunogenic effect of rMOMP adsorption and binding strength to an adjuvant comprising the TLR4 agonist
E6020 and AlOOH, in CD1 mice.
Compositions of Ser E rMOMP and adjuvant were formulated with varying concentrations of phosphate or without
phosphate, and administered to CD1 mice three times intramuscularly. The addition of phosphate reduced the % and strength
of adsorption of rMOMP to the adjuvant. In the composition formulated without phosphate, 100 % of antigen was adsorbed
with high binding strength, whereas in compositions with phosphate, the % and strength of antigen adsorption decreased
with increasing concentrations of phosphate. Each composition was immunogenic in CD1 mice. The composition formulated
without phosphate stimulated specific total IgG production with balanced IgG1/IgG2a subclasses. In contrast, rMOMP
formulated with phosphate induced significantly higher levels of total IgG of predominantly IgG1 subclass, accompanied
by high in vitro neutralizing responses. All compositions with the exception of the one with the highest concentration of
phosphate elicited a Th1/Th17-like immune response with high IFN-γ and IL-17 production and low IL-13. The composition
formulated with the highest concentration of phosphate induced significantly lower IFN-γ and IL-17 production.
Here we described an effective method to modulate the immunogenicity of the AlOOH/E6020 adjuvanted vaccine
candidate.
Biography
Lucian Visan has completed his Ph.D in immunology at Würzburg University, Germany and moved to Mount Sinai Hospital, University of Toronto for postdoctoral
studies. He is now a researcher at Sanofi Pasteur where he leads an immune-bacteriology research unit working on vaccine projects. He has over 10 years of
experience in therapeutic and prophylactic vaccines ranging from cancer to infectious diseases.
